Crystal structure of loteprednol etabonate Form II, C 24 H 31 ClO 7
Source abstract
Abstract
The crystal structure of loteprednol etabonate Form II has been solved and refined using synchrotron X-ray powder diffraction data, and optimized using density functional techniques. Loteprednol etabonate Form II crystallizes in the space group P2 1 (#4) with a = 11.96312(6), b = 14.91862(5), c = 6.75715(3) Å, β = 94.1584(3)°, V = 1202.796(6) Å 3 , and Z = 2. The crystal structure is characterized by herringbone layers in the ab -plane. The anisotropic displacement ellipsoid of the Cl atom is not oriented in a way which corresponds to a chemically sensible motion of this atom. The sample suffered damage in the X-ray beam, probably involving photolysis of the C–Cl bond. The most prominent hydrogen bond is the O–H⋯O hydrogen bond between the hydroxyl group and the carbonyl group of the steroid A ring. This hydrogen bond links the molecules into C 1,1(9) chains along the b -axis. The powder pattern is included in the Powder Diffraction File™ (PDF®) as entry 00-066-1602; this study will allow inclusion of the atomic coordinates to the PDF entry.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: X-ray Diffraction in Crystallography · Crystallography and molecular interactions · Cultural Heritage Materials Analysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (32)
Show source-provided references
1. 10.1021/ci049780b10.1021/ci049780b ↗
2. Pinto, E. (2008). “Sustained release of a soft glucocorticoid loteprednol etabonate using PLA microspheres for the prevention of islet transplantation rejection,” Ph.D. dissertation, University of Florida, Gainesville, FL, USA.
3. 10.1007/BF0054909610.1007/BF00549096 ↗
4. Wang, S. , Han, K. , and Xiu, J. (2015b). “Loteprednol etabonate monohydrate as well as crystal form and preparation thereof,” Chinese Patent Application CN10682953A.
5. 10.1107/S205252061800233010.1107/S2052520618002330 ↗
6. 10.1107/S002188980604211710.1107/S0021889806042117 ↗
7. 10.1107/S090904950801843810.1107/S0909049508018438 ↗
8. 10.1107/S205252061402290210.1107/S2052520614022902 ↗
9. 2018
10. 10.1002/anie.19951555110.1002/anie.199515551 ↗
11. 10.1107/S002188980706790810.1107/S0021889807067908 ↗
12. 10.1107/S010876819901508610.1107/S0108768199015086 ↗
13. 10.1107/S002188981101462210.1107/S0021889811014622 ↗
14. 10.1017/S088571561400051710.1017/S0885715614000517 ↗
15. Turner · 2017
16. 10.1107/S205252061600395410.1107/S2052520616003954 ↗
17. A new law of crystal morphology extending the law of bravais
18. 10.1063/1.296926010.1063/1.2969260 ↗
19. 10.1107/S002188981300353110.1107/S0021889813003531 ↗
20. 10.1002/jcc.2315310.1002/jcc.23153 ↗
21. Silk Scientific (2013). UN-SCAN-IT 7.0 (Silk Scientific Corporation, Orem, UT).
22. Wang, S. , Han, K. , and Xiu, J. (2015a). “Novel loteprednol etabonate crystalline form and preparation thereof,” Chinese Patent Application CN10682952A.
23. 10.1021/ar00172a00510.1021/ar00172a005 ↗
24. 10.1017/S088571561800060X10.1017/S088571561800060X ↗
25. 10.1063/1.46788210.1063/1.467882 ↗
26. 10.1107/S002188981301311310.1107/S0021889813013113 ↗
27. 10.1002/qua.2465810.1002/qua.24658 ↗
28. 10.1017/S088571561900081210.1017/S0885715619000812 ↗
29. Bravais · 1866
30. Etudes sur la loi de Bravais
31. Wavefunction, Inc. (2018). Spartan '18 Version 1.2.0 (Wavefunction Inc., Irvine, CA).
32. 2018